Danaher Withdraws Guidance

This morning, Danaher (DNR) said it’s withdrawing its full-year earnings guidance. The company said that it expects to report Q1 revenue growth of 3%, and non-GAAP core revenue growth of 4.5%.

President and CEO Thomas P. Joyce, Jr. said, “We anticipate positive results in each of our three reporting segments in the first quarter, with particular strength in our Cepheid, Radiometer, Pall and ChemTreat businesses. While we had a good start to the year, we saw a meaningful slowdown in demand toward the end of the quarter, particularly in our more instrument-oriented businesses, as the COVID-19 pandemic spread worldwide.”

Joyce continued, “We are incredibly proud of our team’s response to these unprecedented challenges. We are directly contributing to the fight against this virus, providing much-needed diagnostic testing capabilities and supporting our customers in pursuit of new treatments and vaccines.”

The earnings report will be out on May 7.

Posted by on April 13th, 2020 at 9:21 am


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.